Screening for cancer with molecular markers: Progress comes with potential problems

Nature Reviews Cancer

Volumn 12, Issue 5, 2012, Pages 368-371

  Baron, John A ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BIOLOGICAL MARKER; CA 125 ANTIGEN; PROSTATE SPECIFIC ANTIGEN; VIRUS ANTIGEN;

BREAST CANCER; CANCER SCREENING; CANCER SURGERY; CARCINOGENESIS; CHEMOPROPHYLAXIS; CYTOLOGY; DIAGNOSTIC ERROR; DNA METHYLATION; EARLY DIAGNOSIS; EMISSION TOMOGRAPHY; FALSE POSITIVE RESULT; FLUORESCENCE IMAGING; HISTOLOGY; HORMONE RELEASE; MAMMOGRAPHY; MOLECULAR DIAGNOSIS; NUCLEOTIDE SEQUENCE; ONCOGENE K RAS; PHYSICAL EXAMINATION; PRECANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; REVIEW; SENSITIVITY AND SPECIFICITY; THORAX RADIOGRAPHY;

ANIMALS; BIOLOGICAL MARKERS; EARLY DETECTION OF CANCER; HUMANS; NEOPLASMS;

EID: 84860223306     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3260     Document Type: Review

References (43)

1. Buys, S. S. et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 305, 2295-2303 (2011).
2. Duffy, M. J. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? Clin. Chem. 47, 624-630 (2001). (Pubitemid 32275803)
3. Kulasingam, V., Pavlou, M. P. & Diamandis, E. P. Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer. Nature Rev. Cancer 10, 371-378 (2010).
4. Gigerenzer, G., Mata, J. & Frank, R. Public knowledge of benefits of breast and prostate cancer screening in Europe. J. Natl Cancer Inst. 101, 1216-1220 (2009).
5. Schwartz, L. M., Woloshin, S., Fowler, F. J. Jr & Welch, H. G. Enthusiasm for cancer screening in the United States. JAMA 291, 71-78 (2004). (Pubitemid 38040537)
6. Petricoin, E. F. et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359, 572-577 (2002).
7. Visintin, I. et al. Diagnostic markers for early detection of ovarian cancer. Clin. Cancer Res. 14, 1065-1072 (2008). (Pubitemid 351302552)
8. Ransohoff, D. F. Lessons from controversy: ovarian cancer screening and serum proteomics. J. Natl Cancer Inst. 97, 315-319 (2005). (Pubitemid 40310281)
9. Zhu, C. S. et al. A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev. Res. 4, 375-383 (2011).
10. Division of Cancer Prevention, US National Cancer Institute. The early detection research network, fifth report. NIH Publication 10-7696 (2011).
11. Croswell, J. M., Baker, S. G., Marcus, P. M., Clapp, J. D. & Kramer, B. S. Cumulative incidence of false-positive test results in lung cancer screening: a randomized trial. Ann. Intern. Med. 152, 505-512 (2010).
12. Villanueva, J. et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J. Clin. Invest. 116, 271-284 (2006). (Pubitemid 43121812)
13. Pang, W. W., Abdul-Rahman, P. S., Wan-Ibrahim, W. I. & Hashim, O. H. Can the acute-phase reactant proteins be used as cancer biomarkers? Int. J. Biol. Markers 25, 1-11 (2010).
14. Grubb, R. L. et al. Serum prostate-specific antigen hemodilution among obese men undergoing screening in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiol. Biomarkers Prev. 18, 748-751 (2009).
15. Rundle, A., Richards, C. & Neugut, A. I. Hemodilution of prostate-specific antigen levels among obese men. Cancer Epidemiol. Biomarkers Prev. 18, 2343-2344 (2009).
16. Loeb, S., Gashti, S. N. & Catalona, W. J. Exclusion of inflammation in the differential diagnosis of an elevated prostate-specific antigen (PSA). Urol. Oncol. 27, 64-66 (2009).
17. Lu, H., Ouyang, W. & Huang, C. Inflammation, a key event in cancer development. Mol. Cancer Res. 4, 221-233 (2006).
18. Hussain, S. P. & Harris, C. C. Inflammation and cancer: an ancient link with novel potentials. Int. J. Cancer 121, 2373-2380 (2007). (Pubitemid 350022405)
19. Cole, P. & Morrison, A. S. Basic issues in population screening for cancer. J. Natl Cancer Inst. 64, 1263-1272 (1980). (Pubitemid 10100344)
20. Dorigo, O. & Berek, J. S. Personalizing CA125 levels for ovarian cancer screening. Cancer Prev. Res. 4, 1356-1359 (2011).
21. Black, W. C. Overdiagnosis: an underrecognized cause of confusion and harm in cancer screening. J. Natl Cancer Inst. 92, 1280-1282 (2000). (Pubitemid 30660580)
22. Pollak, M. N. & Foulkes, W. D. Challenges to cancer control by screening. Nature Rev. Cancer 3, 297-303 (2003). (Pubitemid 37328865)
23. Folkman, J. & Kalluri, R. Cancer without disease. Nature 427, 787 (2004). (Pubitemid 38297724)
24. Thompson, I. M. et al. The influence of finasteride on the development of prostate cancer. N. Engl. J. Med. 349, 215-224 (2003). (Pubitemid 36859473)
25. Esserman, L,. Shieh, Y. & Thompson, I. Rethinking screening for breast cancer and prostate cancer. JAMA 302, 1685-1692 (2009).
26. Kovacs, G. L. et al. Epidemiology of thyroid microcarcinoma found in autopsy series conducted in areas of different iodine intake. Thyroid 15, 152-157 (2005). (Pubitemid 40344364)
27. Welch, H. G. & Black, W. C. Using autopsy series to estimate the disease "reservoir" for ductal carcinoma in situ of the breast: how much more breast cancer can we find? Ann. Intern. Med. 127, 1023-1028 (1997). (Pubitemid 27516615)
28. Nielsen, M. Autopsy studies of the occurrence of cancerous, atypical and benign epithelial lesions in the female breast. APMIS Suppl. 10, 1-56 (1989). (Pubitemid 20037352)
29. Biesheuvel, C., Barratt, A., Howard, K., Houssami, N. & Irwig, L. Effects of study methods and biases on estimates of invasive breast cancer overdetection with mammography screening: a systematic review. Lancet Oncol. 8, 1129-1138 (2007). (Pubitemid 350182969)
30. Troyer, D. A. et al. Prostate cancer detected by methylated gene markers in histopathologically cancer-negative tissues from men with subsequent positive biopsies. Cancer Epidemiol. Biomarkers Prev. 18, 2717-2722 (2009).
31. Jaffer, F. A. & Weissleder, R. Molecular imaging in the clinical arena. JAMA 293, 855-862 (2005). (Pubitemid 40250370)
32. Kwon, R. S., Sahani, D. V. & Brugge, W. R. Gastrointestinal cancer imaging: deeper than the eye can see. Gastroenterology 128, 1538-1553 (2005). (Pubitemid 40692551)
33. Wang, T. D. & Van Dam, J. Optical biopsy: a new frontier in endoscopic detection and diagnosis. Clin. Gastroenterol. Hepatol. 2, 744-753 (2004). (Pubitemid 39200712)
34. Marten, K. et al. Detection of dysplastic intestinal adenomas using enzyme-sensing molecular beacons in mice. Gastroenterology 122, 406-414 (2002). (Pubitemid 34116992)
35. Fletcher, R. H. Carcinoembryonic antigen. Ann. Intern. Med. 104, 66-73 (1986). (Pubitemid 16182780)
36. Usadel, H. et al. Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Res. 62, 371-375 (2002). (Pubitemid 34106406)
37. Kawakami, K. et al. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J. Natl. Cancer Inst. 92, 1805-1811 (2000).
38. Sorenson, G. D. Detection of mutated KRAS2 sequences as tumor markers in plasma/serum of patients with gastrointestinal cancer. Clin. Cancer Res. 6, 2129-2137 (2000). (Pubitemid 30399177)
39. Nagasaka, T. et al. Analysis of fecal DNA methylation to detect gastrointestinal neoplasia. J. Natl. Cancer Inst. 101, 1244-1258 (2009).
40. O'Shaughnessy, J. A. et al. Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin. Cancer Res. 8, 314-346 (2002).
41. Cooper, K. et al. Chemoprevention of colorectal cancer: systematic review and economic evaluation. Health Technol. Assess. 14, 1-206 (2010).
42. Cuzick, J. et al. Preventive therapy for breast cancer: a consensus statement. Lancet Oncol. 12, 496-503 (2011).
43. Hruban, R. H., van der Riet, P., Erozan, Y. S. & Sidransky, D. Brief report: molecular biology and the early detection of carcinoma of the bladder-the case of Hubert H. Humphrey. N. Engl. J. Med. 330, 1276-1278 (1994). (Pubitemid 24129961)